Efficient-Pro Medium And Feeds Deliver Strong Product Quality While Enhancing Productivity In CHO-K1 And CHO-S Cells

Once a therapeutic antibody is identified and successfully produced at development scales, manufacturers often consider enhancing productivity as the next challenge for scale-up. Although the importance of strong productivity is undeniable, a more crucial challenge can be delivering sustained or improved product quality with productivity enhancements. Having consistent product quality is essential to ensure patient safety and product efficacy. Impurities can affect downstream purification by requiring additional processes and reducing product yields. Therefore, manufacturers are placing greater emphasis on optimizing upstream processes with the goals of minimizing impurities, improving product quality, and decreasing time to market. The early identification of a robust, commercially available, optimized platform medium and cell line–specific feed could be the keys to achieving strong productivity with sustained or improved product quality and delivering product to market more rapidly.